|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500108583 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-02 09:18:26 |
|
注册时间: Date of Registration: |
2025-09-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
Effects of dance-based multimodal exercise programme for managing chemotherapy-induced peripheral neuropathy in patients with colorectal cancer: A randomized controlled study |
|
Public title: |
Effects of dance-based multimodal exercise programme for managing chemotherapy-induced peripheral neuropathy in patients with colorectal cancer: A randomized controlled study |
|
注册题目简写: |
Effect of dance-based multimodal exercise for managing CIPN in CRC patients |
|
English Acronym: |
Effect of dance-based multimodal exercise for managing CIPN in CRC patients |
|
研究课题的正式科学名称: |
Effects of dance-based multimodal exercise programme for managing chemotherapy-induced peripheral neuropathy in patients with colorectal cancer: A randomized controlled study |
|
Scientific title: |
Effects of dance-based multimodal exercise programme for managing chemotherapy-induced peripheral neuropathy in patients with colorectal cancer: A randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
Lau Ka Yan |
研究负责人: |
Lau Ka Yan |
|
Applicant: |
Lau Ka Yan |
Study leader: |
Lau Ka Yan |
|
申请注册联系人电话: Applicant telephone: |
+852 3702 4260 |
研究负责人电话:
Study leader's |
+852 3702 4260 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1007615222@link.cuhk.edu.hk |
研究负责人电子邮件: Study leader's E-mail: |
1007615222@link.cuhk.edu.hk |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
研究负责人通讯地址: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
|
Applicant address: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
Study leader's address: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||
|
Applicant's institution: |
The Chinese University of Hong Kong |
||
|
研究负责人所在单位: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||
|
Affiliation of the Leader: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025.393-T |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
Joint Chinese University of Hong Kong- New Territories East Cluster Clinical Research Ethics Committee |
||
|
Name of the ethic committee: |
Joint Chinese University of Hong Kong- New Territories East Cluster Clinical Research Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-31 00:00:00 | ||
|
伦理委员会联系人: |
Ms. Amy Li |
||
|
Contact Name of the ethic committee: |
Ms. Amy Li |
||
|
伦理委员会联系地址: |
8/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, HK |
||
|
Contact Address of the ethic committee: |
8/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, HK |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+852 3505 3935 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
crec@cuhk.edu.hk |
|
研究实施负责(组长)单位: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||||||||||||||||||||||
|
Primary sponsor: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||||||||||||||||||||||
|
Primary sponsor's address: |
The Nethersole School of Nursing, The Chinese University of Hong Kong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
Not applicable |
||||||||||||||||||||||
|
Source(s) of funding: |
Not applicable |
||||||||||||||||||||||
|
研究疾病: |
Chemotherapy-induced peripheral neuropathy in colorectal cancer patients |
||||||||||||||||||||||
|
Target disease: |
Chemotherapy-induced peripheral neuropathy in colorectal cancer patients |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
To examine the effects of a dance-based multimodal exercise programme when compared to usual care for the management of CIPN in CRC patients across the 3-month post-intervention period. The objectives include (1) To examine the effects of the programme on CIPN (primary outcome) at immediately, one-month and three-month post-intervention; and (2) To examine the effects of the programme on pain, balance, quality of life and anxiety (secondary outcomes) at immediately, one-month and three-month post intervention; and (3) To examine the effects of the programme on knowledge, motivation and self-efficacy of exercise (process outcomes) at immediately, one-month and three-month post intervention; and (4) To assess any adverse effects of the programme; and (5) To explore the perceived benefits, barriers and areas for improvement after participating the programme. |
||||||||||||||||||||||
|
Objectives of Study: |
To examine the effects of a dance-based multimodal exercise programme when compared to usual care for the management of CIPN in CRC patients across the 3-month post-intervention period. The objectives include (1) To examine the effects of the programme on CIPN (primary outcome) at immediately, one-month and three-month post-intervention; and (2) To examine the effects of the programme on pain, balance, quality of life and anxiety (secondary outcomes) at immediately, one-month and three-month post intervention; and (3) To examine the effects of the programme on knowledge, motivation and self-efficacy of exercise (process outcomes) at immediately, one-month and three-month post intervention; and (4) To assess any adverse effects of the programme; and (5) To explore the perceived benefits, barriers and areas for improvement after participating the programme. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
Not applicable |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Not applicable |
||||||||||||||||||||||
|
纳入标准: |
The inclusion criteria of participants include CRC patients who (1) have received or currently receiving more than one cycle of oxaliplatin-based chemotherapy; and (2) experience CIPN symptoms; and (3) are able to use smart phone and WhatsApp; and (4) are able to read or understand Chinese. |
||||||||||||||||||||||
|
Inclusion criteria |
The inclusion criteria of participants include CRC patients who (1) have received or currently receiving more than one cycle of oxaliplatin-based chemotherapy; and (2) experience CIPN symptoms; and (3) are able to use smart phone and WhatsApp; and (4) are able to read or understand Chinese. |
||||||||||||||||||||||
|
排除标准: |
CRC patients will be excluded from this study when they (1) received neurotoxic chemotherapy other than oxaliplatin, including taxane-based chemotherapy, vinca alkaloids, proteasome inhibitors and thalidomide analogs; or (2) suffer from severe organ failure or diseases that limit their level of activity; or (3) are diagnosed with non-chemotherapy induced peripheral neuropathy, such as sciatica and diabetic neuropathy; or (4) receive treatments that affect the severity of neuropathy, such as steroid, anticonvulsants and antidepressants; or (5) age below 18 years old; or (6) have cognitive impairments. |
||||||||||||||||||||||
|
Exclusion criteria: |
CRC patients will be excluded from this study when they (1) received neurotoxic chemotherapy other than oxaliplatin, including taxane-based chemotherapy, vinca alkaloids, proteasome inhibitors and thalidomide analogs; or (2) suffer from severe organ failure or diseases that limit their level of activity; or (3) are diagnosed with non-chemotherapy induced peripheral neuropathy, such as sciatica and diabetic neuropathy; or (4) receive treatments that affect the severity of neuropathy, such as steroid, anticonvulsants and antidepressants; or (5) age below 18 years old; or (6) have cognitive impairments. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2026-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-15 00:00:00 至 To 2026-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
CRC patients who are fulfilling the eligibility criteria and willing to participate in the programme will be randomized in 1:1 ratio after the baseline measurement. A computer-generated randomization list in a block of four is generated before the randomization. Allocation numbers are concealed in opaque sealed envelopes which only the principal investigator will open them and inform the participants about the program details. |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
CRC patients who are fulfilling the eligibility criteria and willing to participate in the programme will be randomized in 1:1 ratio after the baseline measurement. A computer-generated randomization list in a block of four is generated before the randomization. Allocation numbers are concealed in opaque sealed envelopes which only the principal investigator will open them and inform the participants about the program details. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
An independent assessor will be blinded for the allocation of the participants and intervention. |
|
Blinding: |
An independent assessor will be blinded for the allocation of the participants and intervention. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NA |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Self-reported measures |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Self-reported measures |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |